Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
Repligen (NASDAQ:RGEN) has announced a strategic partnership with Novasign to enhance its bioprocessing digitalization capabilities. The collaboration involves integrating Novasign's machine learning and modeling workflow into Repligen's tangential flow filtration (TFF) systems.
As part of the agreement, Repligen will make an investment in Novasign to support its expansion. The partnership aims to leverage digital twins technology and AI-powered solutions to streamline process development, enable real-time predictive control, and reduce development timelines and costs in bioprocessing operations.
The integration will strengthen Repligen's Process Analytical Technology (PAT)-enabled systems and create opportunities for advanced AI modeling within Repligen platforms.
Repligen (NASDAQ:RGEN) ha annunciato una partnership strategica con Novasign per potenziare le sue capacità di digitalizzazione nei processi biotecnologici. La collaborazione prevede l'integrazione del flusso di lavoro di machine learning e modellazione di Novasign nei sistemi di filtrazione tangenziale (TFF) di Repligen.
Come parte dell'accordo, Repligen investirà in Novasign per supportarne l'espansione. L'obiettivo della partnership è sfruttare la tecnologia dei gemelli digitali e soluzioni basate sull'intelligenza artificiale per ottimizzare lo sviluppo dei processi, abilitare il controllo predittivo in tempo reale e ridurre tempi e costi di sviluppo nelle operazioni biotecnologiche.
Questa integrazione rafforzerà i sistemi di Repligen abilitati alla Process Analytical Technology (PAT) e creerà opportunità per modelli avanzati di intelligenza artificiale all'interno delle piattaforme Repligen.
Repligen (NASDAQ:RGEN) ha anunciado una alianza estratégica con Novasign para mejorar sus capacidades de digitalización en bioprocesos. La colaboración consiste en integrar el flujo de trabajo de aprendizaje automático y modelado de Novasign en los sistemas de filtración tangencial (TFF) de Repligen.
Como parte del acuerdo, Repligen realizará una inversión en Novasign para apoyar su expansión. La asociación busca aprovechar la tecnología de gemelos digitales y soluciones impulsadas por IA para optimizar el desarrollo de procesos, permitir el control predictivo en tiempo real y reducir los tiempos y costos de desarrollo en operaciones de bioprocesamiento.
La integración fortalecerá los sistemas habilitados con Process Analytical Technology (PAT) de Repligen y generará oportunidades para modelos avanzados de IA dentro de las plataformas de Repligen.
Repligen (NASDAQ:RGEN)은 Novasign과 전략적 파트너십을 체결하여 바이오프로세싱 디지털화 역량을 강화한다고 발표했습니다. 이번 협력은 Novasign의 머신러닝 및 모델링 워크플로우를 Repligen의 접선 흐름 여과(TFF) 시스템에 통합하는 것을 포함합니다.
계약의 일환으로 Repligen은 Novasign의 확장을 지원하기 위해 투자를 진행합니다. 이 파트너십은 디지털 트윈 기술과 AI 기반 솔루션을 활용하여 공정 개발을 간소화하고, 실시간 예측 제어를 가능하게 하며, 바이오프로세싱 운영에서 개발 시간과 비용을 줄이는 것을 목표로 합니다.
이 통합은 Repligen의 공정 분석 기술(PAT) 지원 시스템을 강화하고 Repligen 플랫폼 내에서 고급 AI 모델링 기회를 창출할 것입니다.
Repligen (NASDAQ:RGEN) a annoncé un partenariat stratégique avec Novasign afin de renforcer ses capacités de digitalisation des bioprocédés. Cette collaboration consiste à intégrer le flux de travail d'apprentissage automatique et de modélisation de Novasign dans les systèmes de filtration tangentielle (TFF) de Repligen.
Dans le cadre de cet accord, Repligen investira dans Novasign pour soutenir son expansion. Le partenariat vise à exploiter la technologie des jumeaux numériques et les solutions basées sur l'IA pour optimiser le développement des processus, permettre un contrôle prédictif en temps réel, et réduire les délais et coûts de développement dans les opérations de bioprocédés.
Cette intégration renforcera les systèmes de Repligen équipés de la Process Analytical Technology (PAT) et créera des opportunités pour des modélisations avancées par IA au sein des plateformes Repligen.
Repligen (NASDAQ:RGEN) hat eine strategische Partnerschaft mit Novasign angekündigt, um seine Fähigkeiten zur Digitalisierung von Bioprozessen zu verbessern. Die Zusammenarbeit beinhaltet die Integration des Machine-Learning- und Modellierungs-Workflows von Novasign in Repligens Tangentialflussfiltrationssysteme (TFF).
Im Rahmen der Vereinbarung wird Repligen in Novasign investieren, um dessen Expansion zu unterstützen. Ziel der Partnerschaft ist es, die Digital-Twin-Technologie und KI-gestützte Lösungen zu nutzen, um die Prozessentwicklung zu optimieren, eine Echtzeit-Vorhersagesteuerung zu ermöglichen und Entwicklungszeiten sowie Kosten in Bioprozessabläufen zu reduzieren.
Die Integration wird Repligens Systeme mit Process Analytical Technology (PAT) stärken und Chancen für fortschrittliche KI-Modellierung innerhalb der Repligen-Plattformen schaffen.
- Strategic investment and partnership with AI technology leader Novasign
- Integration of advanced machine learning capabilities into existing filtration systems
- Potential reduction in development costs and timelines through digital twins technology
- Enhancement of process analytical technology (PAT) capabilities
- None.
Insights
Repligen's partnership with Novasign combines bioprocessing hardware with AI-powered digital twins, potentially accelerating development and reducing costs for biopharmaceutical manufacturing.
Repligen's strategic partnership with Novasign represents a significant advancement in bioprocessing digitalization with tangible operational benefits. By integrating Novasign's machine learning and modeling capabilities into Repligen's tangential flow filtration (TFF) systems, this collaboration addresses critical industry challenges including long development timelines and high costs.
The partnership's most valuable aspect is the implementation of digital twins - virtual replicas of physical systems that enable simulation and optimization without disrupting actual production. This technology allows companies to predict filtration outcomes, optimize parameters, and troubleshoot issues before they occur in real production environments.
For biopharmaceutical manufacturers, this integration offers potential for significant cost reduction through faster process development and more efficient scale-up operations. The technology combination aims to transform traditional bioprocessing by creating intelligent systems that can predict outcomes, self-optimize, and reduce the extensive experimental work typically required.
Beyond the immediate applications in filtration, this partnership signals Repligen's broader strategic shift toward digitalized bioprocessing across its technology portfolio. By investing directly in Novasign, Repligen is securing preferred access to emerging AI capabilities while helping scale these innovations - suggesting the company sees digital transformation as central to future competitiveness in bioprocessing equipment.
The collaboration builds on previous joint efforts between the companies, indicating this isn't merely exploratory but an extension of proven technological synergies. For bioprocess engineers and manufacturing leads, this partnership promises tools that could fundamentally change how biopharmaceutical processes are developed and controlled.
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign’s machine learning and modeling workflow into Repligen filtration systems. As part of the partnership, Repligen will invest in Novasign to help scale and expand operations.
Through this collaboration, Novasign’s unique modeling workflow will be integrated into Repligen’s tangential flow filtration (TFF) systems. This will not only enhance Repligen’s digitalization journey and strengthen its portfolio of process analytical technology (PAT)-enabled systems but also unlock the potential for future advanced AI modeling within Repligen platforms. The end goal is to streamline process development, enable real-time predictive control, and significantly reduce development timelines and costs through the deployment of digital twins.
Novasign brings together deep expertise in bioprocessing, modeling, and software engineering to deliver AI-powered solutions across cultivation, harvest, filtration, and chromatography. The company’s flexible, multi-use models extract actionable insights from experimental data and can be readily applied to new modalities, products, and scales. The net result is smarter process development, enhanced monitoring and control, and a significant reduction in time, cost, and risk.
Ralf Kuriyel, Senior Vice President, Research and Development at Repligen, said, “We are excited to partner with Novasign, a leader in bioprocessing modeling technology. Our partnership underscores Repligen’s dedication to advancing toward smart digital manufacturing. By integrating our automated manufacturing systems with smart sensors and Novasign’s digital twins capability, we will provide technology to accelerate process development and ensure a more efficient and reliable scale-up for our customers.”
Mark Duerkop, Chief Executive Officer at Novasign, added, “The fusion of intelligent modeling workflows, PAT and smart devices will allow the industry to drastically reduce development costs while unlocking deeper process understanding. We’ve already laid the groundwork for this collaboration through earlier joint efforts with Repligen on its PAT technologies, and we’re proud to now take it to the next level with joint development. This strategic partnership represents a strong endorsement of Novasign’s innovation and long-term role in advancing bioprocess digitalization.”
About Novasign
Founded in 2019 as a spin-off from BOKU University, Novasign is headquartered in Vienna, Austria, and is rapidly becoming a central enabler of bioprocessing 4.0. The company accelerates bioprocess development through smart experimental workflows and an intuitive modeling platform. Its software transforms data from cultivation, harvest, filtration, and chromatography into extensible digital twins, enabling data-driven optimization for mAbs, ATMPs, enzymes, and cultured-food processes. By embedding advanced modeling directly into experimental workflows, Novasign shortens development timelines, reduces costs, and deepens process understanding. For more information, visit https://novasign.at. and follow us on LinkedIn.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information, please visit www.repligen.com, and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to and in reliance upon the safe harbor provisions of federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein which do not describe historical facts, including, among others, any express or implied statements or guidance regarding current or future financial performance and position, including our 2025 financial guidance and related assumptions; expected demand in the markets in which we operate; expectations regarding the acquisition of 908 Devices’ bioprocessing portfolio; and the expected performance of our business and momentum across our portfolio, are based on management’s current expectations and beliefs and are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.
Such risks and uncertainties include, among others, our ability to successfully grow our bioprocessing business; our ability to manage through and predict headwinds; the risk that we have assumed that markets and franchises will improve and grow more than expected; our ability to achieve our 2025 financial guidance; our ability to develop and commercialize products and the market acceptance of our products; our ability to successfully integrate any acquired businesses and relevant personnel in a timely manner or at all, and to achieve the expected benefits of such acquisitions; that demand for our products could decline, which could adversely impact our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing companies; risks around the Company’s effectiveness of disclosure controls and procedures and the effectiveness of our internal control over financial reporting; our compliance with all U.S. Food and Drug Administration and European Medicines Evaluation Agency regulations; our volatile stock price; the impact of tariffs on our business, and other risks and uncertainties detailed in Repligen’s filings with the U.S. Securities and Exchange Commission (the Commission), including our Annual Report on Form 10-K for the year ended December 31, 2024 and in subsequently filed reports with the Commission, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and any subsequent filings made with the Commission, which are available at the Commission’s website at www.sec.gov. Actual results may differ materially from those Repligen contemplated by these forward-looking statements, which reflect management’s current views, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and are based only on information currently available to us. Repligen cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Repligen disclaims any obligation to update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Contact:
Jacob Johnson
VP, Investor Relations
(781) 419-0204
investors@repligen.com
Contact:
Mark Duerkop
Chief Executive Officer
0043 660 10 17 239
management@novasign.at
FAQ
What is the purpose of Repligen's partnership with Novasign?
How will the Novasign partnership benefit Repligen's customers?
What technologies will be integrated into Repligen's systems through this partnership?
What areas of bioprocessing will Novasign's technology cover in the partnership?
